Co-incubation of Linvoseltamab with Jurkat cells, then with the addition of huBCMA-HEK293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Linvoseltamab was able to activate the NF-AT signaling pathway, and the EC50 was 0.678 nM.

Linvoseltamab bound to huBCMA-HEK293 cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Linvoseltamab bound to huBCMA-HEK293 cells, and the EC50 was 2.486 nM.

Linvoseltamab bound to Jurkat cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Linvoseltamab bound to Jurket cells, and the EC50 was 11.160 nM.

Linvoseltamab bound to BCMA protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Linvoseltamab bound to huBCMA-ECD-His, and the EC50 was 0.096 nM.

The purity of Anti-BCMA & CD3 Reference Antibody (Linvoseltamab) is 97.71%, determined by SEC-HPLC.

Anti-BCMA & CD3 Reference Antibody (Linvoseltamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The detected molecular weight of Anti-BCMA & CD3 Reference Antibody (Linvoseltamab) is 145.95 kDa.